The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

被引：0

作者：

Mutlu Hizal

Burak Bilgin

Nail Paksoy

Özgür Açıkgöz

Ahmet Sezer

Mustafa Gürbüz

Naziye Ak

Şebnem Yücel

Murat Ayhan

Cihan Erol

Aykut Demirkıran

Nil Molinas Mandel

Abdallah Shbair

İvo Gökmen

Tuğba Başoğlu

Semra Paydaş

Atike Gökçen Demiray

Yakup İriağaç

Teoman Şakalar

Esra Zeynelgil

Ali Murat Tatlı

Aykut Bahçeci

Deniz Can Güven

Burcu Caner

Alper Can

Ahmet Gülmez

Yusuf Karakaş

Bülent Yalçın

Ahmet Demirkazık

Ahmet Bilici

Adnan Aydıner

Perran Fulden Yumuk

Mehmet Ali Nahit Şendur

机构：

[1] Ankara City Hospital,Department of Medical Oncology

[2] Atatürk Chest Disease and Chest Surgery Research and Education Hospital,Department of Medical Oncology

[3] İstanbul University, Department of Medical Oncology, İstanbul Faculty of Medicine

[4] Medipol University,Department of Medical Oncology

[5] Faculty of Medicine,Department of Medical Oncology

[6] Başkent University,Department of Medical Oncology

[7] Faculty of Medicine,Department of Medical Oncology

[8] Ankara University,Department of Medical Oncology

[9] Faculty of Medicine,Department of Medical Oncology

[10] Yozgat City Hospital,Department of Medical Oncology, Meram Faculty of Medicine

[11] Kartal Lütfi Kırdar City Hospital,Department of Medical Oncology

[12] Yıldırım Beyazıt University Faculty of Medicine,Department of Medical Oncology

[13] Necmeddin Erbakan University,Department of Medical Oncology, Faculty of Medicine

[14] American Hospital,Division of Medical Oncology

[15] Bezmialem University Faculty of Medicine,Department of Medical Oncology

[16] Trakya University,Department of Medical Oncology

[17] Marmara University School of Medicine,Department of Medical Oncology

[18] Çukurova University Faculty of Medicine,Department of Medical Oncology

[19] Pamukkale University Faculty of Medicine,Department of Medical Oncology

[20] Namık Kemal University Faculty of Medicine,Department of Medical Oncology

[21] Necip Fazıl City Hospital,Department of Medical Oncology

[22] Dışkapı Education and Research Hospital,Department of Medical Oncology

[23] Akdeniz University Faculty of Medicine,Department of Medical Oncology

[24] Ersin Arslan Education and Research Hospital,Department of Medical Oncology

[25] Hacettepe University Faculty of Medicine,Department of Medical Oncology

[26] Uludağ University Faculty of Medicine,Department of Medical Oncology

[27] İstinye University Faculty of Medicine,undefined

[28] İnönü University Faculty of Medicine,undefined

[29] Bodrum Acıbadem Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

Osimertinib; Non-small cell lung cancer; EGFR; T790M; Second line;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1501 / 1508

页数：7

共 50 条

[21] Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
Kotake, M.
Murakami, H.
Naito, T.
Takahashi, T.
Kenmotsu, H.
Ono, A.
Wakuda, K.
Nakashima, K.
Omori, S.
ANNALS OF ONCOLOGY, 2016, 27
[22] Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer
Jenkins, Suzanne
Yang, James C-H.
Ramalingam, Suresh S.
Yu, Karen
Patel, Sabina
Weston, Susie
Hodge, Rachel
Cantarini, Mireille
Janne, Pasi A.
Mitsudomi, Tetsuya
Goss, Glenwood D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) : 1061 - 1070
[23] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).
De Marinis, Filippo
Cho, Byoung Chul
Kim, Dong-Wan
Kim, Sang-We
Hochmair, Maximilian J.
Metro, Giulio
Vansteenkiste, Johan F.
Vicente, David
Solomon, Benjamin J.
Cheema, Parneet K.
Freitas, Helano C.
Provencio, Mariano
Chen, Yuh-Min
Wu, Yi-Long
Milner, Alvin
Rigas, James R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study
Takahama, Takayuki
Azuma, Koichi
Shimokawa, Mototsugu
Takeda, Masayuki
Ishii, Hidenobu
Kato, Terufumi
Saito, Haruhiro
Daga, Haruko
Tsuboguchi, Yuko
Okamoto, Isamu
Otsubo, Kohei
Akamatsu, Hiroaki
Teraoka, Shunsuke
Takahashi, Toshiaki
Ono, Akira
Ohira, Tatsuo
Yokoyama, Toshihide
Sakai, Kazuko
Yamamoto, Nobuyuki
Nishio, Kazuto
Nakagawa, Kazuhiko
CANCER, 2020, 126 (09) : 1940 - 1948
[25] The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis
Guo, Liuxian
Zhou, Guojin
Huang, Min
Tang, Kejing
Xu, Jing
Chen, Jie
CLINICAL RESPIRATORY JOURNAL, 2024, 18 (04):
[26] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer
Lee, Jang Ho
Kim, Eun Young
Park, Cheol-Kyu
Lee, Shin Yup
Lee, Min Ki
Yoon, Seong-Hoon
Lee, Jeong Eun
Lee, Sang Hoon
Kim, Seung Joon
Lee, Sung Yong
Lim, Jun Hyeok
Jang, Tae -Won
Jang, Seung Hun
Lee, Kye Young
Lee, Seung Hyeun
Yang, Sei Hoon
Park, Dong Won
Park, Chan Kwon
Kang, Hye Seon
Yeo, Chang Dong
Choi, Chang-Min
Lee, Jae Cheol
CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 112 - 122
[27] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
Garcia Samblas, Victoria
Fernandez Madrigal, Laura
Rodriguez Garces, Maria Yeray
Inoriza, Angel
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in THAILAND
Prempree, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
[29] ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)
Cheema, P. K.
Chen, Y-M.
de Marinis, F.
Freitas, H. C.
Kim, S-W.
Milner, A.
Provencio, M.
Rigas, J.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2017, 28
[30] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
Imamura, Fumio
Kimura, Madoka
Yano, Yukihiro
Mori, Masahide
Suzuki, Hidekazu
Hirashima, Tomonori
Ihara, Shouichi
Komuta, Kiyoshi
Shiroyama, Takayuki
Nagatomo, Izumi
Kumagai, Toru
FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546

← 1 2 3 4 5 →